$13.70
Today
as of Aug 5, 16:52 ET
Last 30 days
Recent Press Releases & News
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
Overview
52-week range
$7.56
$20
51% of range
Avg surprise (last 3)
+14.2%
Avg reaction (last 2)
-1.2%
50% positive
Latest IV / EM
218%
EM ±36.5% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.13 | $-0.19 | +31.6% | +38.1% | +0.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.11 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.26 | $-0.24 | -8.3% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.21 | $-0.26 | +19.2% | — | -3.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.19 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.32 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.28 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.36 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.19 | -$0.26 | +26.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22M | — | $27M | $24M | $23M | — | $21M | $19M |
| Cost of revenue | $4M | — | $6M | $5M | $5M | — | $6M | $5M |
| Gross profit | $18M | — | $21M | $18M | $17M | — | $15M | $14M |
| Operating income | $-6M | — | $-3M | $-7M | $-5M | — | $-4M | $-6M |
| Net income | $-7M | — | $-3M | $-9M | $-7M | — | $-5M | $-8M |
| EPS (diluted) | $-0.20 | — | $-0.11 | $-0.26 | $-0.21 | — | $-0.19 | $-0.26 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15M | $22M | $21M | $23M | $27M | $13M | $15M | $13M |
| Inventory | $17M | $17M | $18M | $16M | $14M | $13M | $12M | $11M |
| Total current assets | $87M | $94M | $95M | $94M | $97M | $81M | $83M | $80M |
| Total assets | $99M | $106M | $107M | $106M | $110M | $95M | $96M | $94M |
| Long-term debt | $59M | $59M | $59M | $59M | $60M | $60M | $59M | $59M |
| Total liabilities | $84M | $87M | $89M | $87M | $86M | $87M | $86M | $85M |
| Total equity | $14M | $19M | $19M | $19M | $24M | $8M | $10M | $10M |